Abstract
Backgrounds Children and adolescents form a large proportion of societies and play an important role in the transmission of COVID-19. On the other hand, their education, mental and physical wellness, and safety are compromised which makes vaccination a crucial step to return to normal life.
Aims and objectives To collect and summarize all data about the immune response, effectiveness, and safety of available COVID-19 vaccines for people aged 2 – 21 years old.
Methods A thorough systematic review was performed on available publications in English language regarding immunogenicity, efficacy, and safety of COVID-19 vaccines in individuals aged 2 – 21 years old. Types of selected studies were clinical trials, observational studies, and cohort. Searched databases comprised Ovid Medline, Cochrane Library, Embase, Scopus, Web of Sciences, Google Scholar, and ClinicalTrials.gov website. Data extraction and analysis were performed in Microsoft Word software, version 16.56.
Results The COVID-19 vaccination was evaluated in a total of 50,148 children and adolescents in 22 published studies and 5,279 participants in two ongoing clinical trials. Data were collected about multiple vaccines including BNT162b2 (Pfizer), mRNA-1273 (Moderna), JNJ-78436735 (Johnson and Johnson), CoronaVac (Sinovac), BBIBP-CorV (Sinopharm), adenovirus type-5-vectored vaccine, ZyCov-D, and BBV152 (COVAXIN). The immune response and efficacy of such vaccines were 96% – 100% in healthy children and adolescents and were also acceptable in those with underlying diseases and suppressed immune systems. The current systematic review revealed favorable safety profiles of employed vaccines in children and adolescents; however, adverse reactions such as myocarditis and myopericarditis were reported which were transient and resolved entirely.
Conclusion Vaccinating children and adolescents aged 2 – 21 years old is beneficial to abort the COVID-19 pandemic. Moreover, the risk-benefit assessments revealed favorable results for vaccinating children and adolescents, especially those with underlying disease, alongside adults to prevent transmission, severe infection, negative outcomes, and new variants formation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research received no external funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Authors Information:
1. Sara Sadeghi, M.D., Division of Dermatology, Department of Pediatrics, University of Calgary, Alberta Children’s Hospital, 28 Oki Dr NW, Calgary, AB, Canada, sarasadeghimd{at}gmail.com, sara.sadeghi1{at}ucalgary.ca, Cell phone: 0014039037600
2. Yasamin Kalantari, M.D., Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran, Address: Razi Hospital, Vahdat-e-eslami Square, Tehran, Iran, Postal code: 1199663911, yasamin.kalantari{at}gmail.com, Cell phone: 0098912885894
3. Sima Shokri, M.D., Assistant Professor, Department of Pediatrics, Allergy and Clinical Immunology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences, Tehran, Iran, Shokri.s{at}IUMS.ac.ir, Cell phone: 00989122951812
4. Morteza Fallahpour, M.D., Assistant Professor, Department of Pediatrics, Allergy and Clinical Immunology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences, Tehran, Iran, Fallahpour.morteza{at}yahoo.com, Cell phone: 00989111264407
5. Nahid Nafissi, M.D., Department of General Surgery, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences, Tehran, Iran, Nafissi.n{at}iums.ac.ir, Cell phone: 00989121939395
6. Azadeh Goodarzi, M.D., Associate Professor of Dermatology, Department of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran, Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Iran Jordan Dermatology and Hair Transplantation Center, Tehran, Iran, Address: Rasool Akram Medical Complex, Sattarkhan Avenue, Niayesh Street, Tehran, Iran, Postal Code: 1445613131, azadeh_goodarzi1984{at}yahoo.com, goodarzi.a{at}iums.ac.ir, Cell Phone: 00989123882448, Phone Number: 00982166502040
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- (SARS-CoV-2)
- Severe acute respiratory syndrome coronavirus 2
- (PRISMA)
- Preferred Reporting Items for Systematic reviews and Meta-Analysis
- (Ab)
- antibodies
- (CVID)
- adenovirus type-5(Ad5), common variable immunodeficiency
- (unPAD)
- unclassified pediatric antibody deficiency
- (IBD)
- Inflammatory bowel disease
- (JNJ)
- Johnson & Johnson
- (KTRs)
- kidney transplant recipients
- (JIA)
- juvenile inflammatory arthritis